• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Latest News

Fluid biomarkers in MS – the year in review

November 25, 2024  

SPECIAL REPORT

NfL
GFAP
CHIT1

Read More

TOPICS: BIOMARKERS IN MS

High-efficacy DMTs in MS – the year in review

November 14, 2024  

SPECIAL REPORT

Intensive therapy vs. escalation
Long-term data
B cell depletion and EBV
New formulation
Treatment discontinuation

Read More

TOPICS: MS

Cenobamate as adjunctive therapy for partial-onset seizures: a review

October 25, 2024  

SPECIAL REPORT

Mechanism of action
Efficacy and safety studies
Use of adjunctive cenobamate in practice

Quick poll on epilepsy management
Submit your answers to reveal how your colleagues voted (respondents remain anonymous)

Read More

TOPICS: EPILEPSY

Pregnancy and MS – new data from ECTRIMS

October 17, 2024  

SPECIAL REPORT

Pregnancy and MS
Effect of treatment on postpartum relapses
Pregnancy outcomes in treated patients
Fetal and neonate drug exposure with ocrelizumab

Quick poll on pregnancy and MS
Submit your answers to reveal how your colleagues voted (respondents remain anonymous)

Read More

TOPICS: ECTRIMS 2024, MS
Previous
5
6
7
8
9
Next

Browse by Topic

  • MS (414)
  • CLINICAL CASES IN MS (16)
  • EPILEPSY (36)
  • BIOMARKERS IN MS (54)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • Library (17)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • DMT prescribing in Canada – survey results posted on June 6, 2025
  • CLINICAL CASES IN MS: A 42 Y.O. WOMAN WITH A SEVERE RELAPSE ON DMF posted on June 2, 2025
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2025 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions